

# PreadyPort MDR1 96-wells Drug-Transporter Interactions Experimental Data

Apparent Permeability ( $P_{app}$ ) values and Efflux Ratios (ER) for the MDR1 substrates, digoxin and quinidine, in the absence/presence of verapamil and valsopodar, two reference inhibitors. Assays were performed after exposing MDR1-overexpressing cells (**PreadyPort MDR1**) and those expressing the empty vector (**PreadyPort WT**) to the shipping medium during a 4-day period and a subsequent 72-hr recovery in fresh culture medium. *These data are the result of 3 independent experiments.*

■  $P_{app}$  A-B   ■  $P_{app}$  B-A




Figure 1. Digoxin secretory transport.




Figure 2. Digoxin secretory transport (batch-to-batch variation).




Figure 3. Quinidine secretory transport.




Figure 4. Quinidine secretory transport (batch-to-batch variation).

## Quality Controls

Transepithelial Electrical Resistance (TEER) and Lucifer Yellow Paracellular Permeability were employed to evaluate PreadyPort cell barrier integrity. Assays were performed before (pre-) and after (post-) adding the shipping medium for delivery.

■ PreadyPort WT   ■ PreadyPort MDR1   ■ LY Permeability   ● LY Flux




Figure 5. Changes in TEER values throughout the PreadyPort manufacturing process. *These data are the result of 3 different batches.*




Figure 6. Lucifer Yellow Paracellular Permeability ( $P_{app}$ ) before (pre-shipment) and after (post-shipment) adding the shipping medium. *These data are the result of 3 different batches.*




Figure 7. Effect of DMSO on barrier integrity of PreadyPort cell monolayers. *These data refer to a single experiment in triplicates.*

MDR1 regulatory requirements are detailed in the 2020 FDA and 2012 EMA Drug Interaction Guidelines.